Tm Bioscience Appoints Two New Directors
TORONTO, June 3 /CNW/ - VSE - TMC Tm Bioscience, a leader in the
development of DNA (nucleic acids) technologies, is pleased to announce the appointment of Mark L. Pearson, Ph.D., Biotechnology Consultant and Neil M. Reid, Ph.D., Senior Vice-President of MDS Sciex to the Company's Board of Directors.
Dr. Pearson currently serves as a consultant to the biotechnology
industry focusing on genomics and proteomics and their applications to small molecule drug discovery. Prior to his current role, Dr. Pearson served as President of Molecumetics, Ltd, a drug design and synthesis company. Previous to Molecumetics, he was President and CEO of Darwin Molecular Corporation, a enomics and combinatorial chemistry company. Dr. Pearson currently serves on the Boards of the Canadian Genetic Disease Network and Base4 Bioinformatics Inc.
Dr. Reid is co-founder and Senior Vice-President of MDS Sciex, a leading health and life sciences company. He also is the General Manager of Perkin Elmer Sciex Instruments, a joint venture between MDS Sciex and Perkin Elmer. Previously, Dr. Reid held the positions of Vice-President Marketing and Vice-President Research and Development at Sciex. He is the co-founder of the Canadian Contract Research Administrators Association and currently serves on
the Board of Perkin Elmer Sciex Instruments.
''Dr. Pearson and Dr. Reid bring a wealth of life science experience to our Board,'' said Richard Lockie, Tm Bioscience's Chairman. ''Their presence will assist the Company in providing strategic introductions and direction for Tm's future growth.''
Tm Bioscience is an emerging Canadian biotechnology company developing and commercializing proprietary DNA based technologies for application in biochips, diagnostics and genomic analysis. The Company offers pharmaceutical and biotechnology companies the ability to develop novel nucleic acid-based products for medical and research applications. Additional information about Tm Bioscience can be found at www.tmbioscience.com.
Tm Bioscience trades on the Vancouver Stock Exchange under the symbol TMC and has approximately 69 million shares outstanding.
THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT
RESPONSIBILITY FOR THE ADEQUACY AND ACCURACY OF THIS NEWS RELEASE
%SEDAR: 00005375E
-0- 06/03/1999
For further information: Don MacAdam, President & CEO, (416) 593-4323, (416) 593-1066 fax, dmacadam@tmbioscience.com; Jay Hussey, Investor and Media Inquiries, (416) 815-0700 ext. 225, (416) 815-0080 fax, jhussey@equicomgroup.com
|
